Tumor dynamics obtained from KRAS monitoring could provide important information about treatment strategies for patients with mCRC, such as detection of drug resistance to anti-EGFR antibody before radiographic documentation of disease progression [10, 9, 19]. The gene discussed is EGFR; the disease is neoplasm.